These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29306240)

  • 21. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?
    Greer LT; Rosman M; Mylander WC; Hooke J; Kovatich A; Sawyer K; Buras RR; Shriver CD; Tafra L
    J Am Coll Surg; 2013 Feb; 216(2):239-51. PubMed ID: 23141136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
    Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
    J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X; Yuan Y; Gu Z; Shen K
    Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM
    Histopathology; 2024 Sep; 85(3):437-450. PubMed ID: 38651302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
    Yin HF; Wang YH; Qin XQ; Zhang H; Li T; Ye JM; Liu YH
    Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):858-62. PubMed ID: 20137353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors.
    Choi JS; Baek HM; Kim S; Kim MJ; Youk JH; Moon HJ; Kim EK; Han KH; Kim DH; Kim SI; Koo JS
    PLoS One; 2012; 7(12):e51712. PubMed ID: 23272149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
    Pu T; Shui R; Shi J; Liang Z; Yang W; Bu H; Li Q; Zhang Z;
    BMC Cancer; 2019 Oct; 19(1):978. PubMed ID: 31640622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.
    Na S; Kim M; Park Y; Kwon HJ; Shin HC; Kim EK; Jang M; Kim SM; Park SY
    Breast Cancer; 2024 Jul; 31(4):705-716. PubMed ID: 38643429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer].
    Yuan Y; Hu SN; Gao J; Yu Q; Hu YQ; Xu XY; Gao ZG; Zhang J; Zhang Z; Teng Y; Zhang LL
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):681-685. PubMed ID: 31550858
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer.
    Qin Q; Gao F; Jiang W; Tan Q; Mo Q; Wei C
    Chin Med J (Engl); 2014; 127(18):3272-7. PubMed ID: 25266526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers.
    Kim HS; Park S; Koo JS; Kim S; Kim JY; Nam S; Park HS; Kim SI; Park BW
    PLoS One; 2016; 11(3):e0151054. PubMed ID: 26954364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
    Mann GB; Fahey VD; Feleppa F; Buchanan MR
    J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients.
    Tamaki K; Sasano H; Ishida T; Miyashita M; Takeda M; Amari M; Tamaki N; Ohuchi N
    Cancer Sci; 2010 Sep; 101(9):2074-9. PubMed ID: 20557310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors.
    Petrau C; Clatot F; Cornic M; Berghian A; Veresezan L; Callonnec F; Baron M; Veyret C; Laberge S; Thery JC; Picquenot JM
    Am J Clin Pathol; 2015 Oct; 144(4):555-62. PubMed ID: 26386076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
    Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
    Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.